Ionis Pharmaceuticals specializes in the discovery and development of RNA-targeted drugs.
Ionis Pharmaceuticals is a pharmaceutical company. It specializes in RNA-targeted drug discovery and development. Ionis has developed antisense technology, an efficient, broadly applicable drug discovery platform that can treat diseases where no other therapeutic approaches have proven effective.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 8, 2021 | Post-IPO Debt | $550M | — | — | — | Detail |
Aug 27, 2012 | Post-IPO Debt | $201.25M | — | — | — | Detail |
May 24, 1991 | IPO | — | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Nov 14, 2022
Metagenomi
|
Corporate Round | $80M | Artificial Intelligence | Yes |
Jan 5, 2021
Aro Biotherapeutics
|
Series A | $88M | Biotechnology | — |
Jan 9, 2020
Empirico
|
Series A | $17M | Biotechnology | Yes |
Mar 1, 2007
Atlantic Healthcare
|
Seed | $6.80M | Biotechnology | Yes |
Ionis Pharmaceuticals has acquired 1 organizations. Their most recent acquisition was Akcea Therapeutics on Aug 31, 2020. They acquired Akcea Therapeutics for $500M.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Aug 31, 2020
Akcea Therapeutics
|
Biotechnology | acquisition | $ 500M | Detail |